Literature DB >> 1425493

Pregnancy and the risk of teratogenicity.

D Lindhout1, J G Omtzigt.   

Abstract

One in every 250 newborns is exposed to antiepileptic drugs (AEDs) in utero. Various studies have attributed a teratogenic effect to these AEDs, mainly consisting of major malformations, minor anomalies, intrauterine or postnatal growth failure, and psychomotor retardation. Prospective studies confirm the increased risk of major malformations. The absolute risk of 7-10% is about 3-5% higher than that in the general population. Barbiturates and phenytoin (PHT) are particularly associated with congenital heart malformations, facial clefts, and some other malformations. Valproate (VPA) and carbamazepine (CBZ) are associated predominantly with spina bifida aperta (1-2 and 0.5-1.0% risk, respectively) and hypospadias. Bilateral radial aplasia is a rare but specific effect of VPA. Several studies identified additional risk factors, i.e., high daily AED dosage, high maternal serum AED concentrations, low folate levels, or polytherapy [phenobarbital (PB) plus primidone (PRM) plus PHT or CBZ plus VPA plus PB with or without PHT]. The few prospective studies controlled for socioeconomic factors or that considered parental findings indicate that risk of specific cognitive defects rather than risk of overall mental retardation may be increased, that early growth retardation is followed by a catch-up growth to normal, and that ocular hypertelorism and nail hypoplasia are the only minor anomalies causally related to PHT exposure. However, no final conclusions can be made. Genetic predisposition to the teratogenic side effects of AEDs plays a role, codetermining the recurrence risk if the woman has previously given birth to a child with a major malformation. The molecular genetic basis of this predisposition is unclear.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425493     DOI: 10.1111/j.1528-1157.1992.tb06226.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

Review 1.  Antiepileptic drugs and neurodevelopment.

Authors:  Gholam K Motamedi; Kimford J Meador
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

Review 2.  Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing?

Authors:  Carmela Palmieri; Raffaele Canger
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  Management of epilepsy in women of childbearing age: practical recommendations.

Authors:  Barbara Tettenborn
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Valproic acid in epilepsy : pregnancy-related issues.

Authors:  Pierre Genton; Franck Semah; Eugen Trinka
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Teratogenicity of antiepileptic medications.

Authors:  Benzi M Kluger; Kimford J Meador
Journal:  Semin Neurol       Date:  2008-07-24       Impact factor: 3.420

Review 6.  Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research.

Authors:  Kevin G Bath; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-08       Impact factor: 2.937

7.  Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism.

Authors:  Ji-Woon Kim; Hana Seung; Kyung Ja Kwon; Mee Jung Ko; Eun Joo Lee; Hyun Ah Oh; Chang Soon Choi; Ki Chan Kim; Edson Luck Gonzales; Jueng Soo You; Dong-Hee Choi; Jongmin Lee; Seol-Heui Han; Sung Min Yang; Jae Hoon Cheong; Chan Young Shin; Geon Ho Bahn
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

Review 8.  Use of lipid-lowering medicinal herbs during pregnancy: A systematic review on safety and dosage.

Authors:  Hojjat Rouhi-Boroujeni; Esfandiar Heidarian; Hamid Rouhi-Boroujeni; Minasadat Khoddami; Mojgan Gharipour; Mahmoud Rafieian-Kopaei
Journal:  ARYA Atheroscler       Date:  2017-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.